

Health outcomes may be valued using the willingness-to-pay method.⁴ This measurement technique tries to gauge how much society is willing to pay to lower the risk of death due to a specific illness or disease. For example, consider a group of 100,000 people who participate in a flu shot program. Let's assume five will die of the flu. If all are willing to pay \$10 each to reduce the number of flu-related deaths to three, then the "value" per life saved is \$500,000 (100,000 people × \$10 per person = \$1,000,000 ÷ 2 lives saved = \$500,000 per life saved).

This example illustrates two disadvantages to cost-benefit analysis:

- First, it might not include every program outcome because the analysis can ignore externalities associated with the program. Externalities are costs and benefits that have an impact on individuals who are not directly affected by a program. All participants in the program receive the direct benefit of lowering their risk of getting the flu. The benefits go beyond just the program's participants because individuals not vaccinated through the program are also less prone to getting the flu because of fewer potential flu carriers. The willingness-to-pay method may not account for this added benefit.

- Second, this method relies on the difficult and controversial task of measuring the value of human life, which is one reason why economics earns its reputation as the dismal science. Because placing a value on life is so difficult and considered by some to be amoral, cost-effectiveness analysis is a more common and acceptable way to evaluate health programs.

Unlike a cost-benefit analysis, a cost-effectiveness analysis does not assign a dollar value to each outcome. Instead, it measures outcomes using an effectiveness measure that is specific to the program being evaluated; for a flu shot program, it would likely be the reduction in the percentage of people who get the flu.⁵

Cost-effectiveness analysis is beneficial when comparing programs with common outcomes, such as a flu program in a hospital with a flu program in a nursing home. Rather than measuring what society is willing to pay to avoid a disease or illness, health outcomes are thought of in terms of the costs that are saved as a result of the program. Ill people incur medical costs for treatment and lost income due to time taken away from work. Because the program saves the costs by preventing illness, the costs are subtracted from the cost of implementing the program to arrive at the program's net cost. For a flu program, this net cost is then divided by the num-

ber of flu cases prevented to obtain a cost for each flu case prevented.

So, how have economic evaluations been used? The accompanying table shows the results of a few cost-benefit studies that estimate the benefit of flu vaccinations in healthy, working adults. The costs were not estimated using the willingness-to-pay method. A minus before a cost (as in -\$6.65) means society does not receive a benefit in that cost category. The net cost savings range from \$13.66 to \$83.84.

The results from these studies vary because of different study settings, different prices used to estimate costs and different assumptions about the amount of medical care needed to treat the flu. Despite these differences, the studies suggest that, overall, society benefits from flu vaccinations.

Conclusion

How does figuring the costs and benefits of a health program help us out? Economic evaluations go beyond pure efficacy of health programs and determine the efficient allocation of scarce health resources. They provide a very useful framework that helps policymakers in Washington make better decisions when thinking about which health programs to endorse and fund. Simply put, economic evaluations allow our country's leaders to choose the health programs that provide the greatest benefit to our society.

Charles Hokayem is a research associate at the Federal Reserve Bank of St. Louis.

ENDNOTES

- 1 Drummond et al. (1997).
- 2 Haddix et al. (1996).
- 3 Haddix et al. (1996).
- 4 Haddix et al. (1996).
- 5 Haddix et al. (1996).

REFERENCES

Dille, JoAnne Hein. "A Worksite Influenza Immunization Program." *Official Journal of the American Association of Occupational Health Nurses*, July 1999, Vol. 47, No. 7, pp. 301-9.

Drummond, Michael; O'Brien, Bernie; Stoddart, Greg and Torrance, George, eds. *Methods for the Economic Evaluation of Health Care Programmes*. Oxford: Oxford University Press, 1997.

Haddix, Anne C.; Teutsch, Steven M.; Shaffer, Phaedra and Dunet, Diane, eds. *Prevention Effectiveness: A Guide to Decision Analysis and Economic Evaluation*. Oxford: Oxford University Press, 1996.

Nichol, Kristin L. "Cost-Benefit Analysis of a Strategy to Vaccinate Healthy Working Adults Against Influenza." *Archives of Internal Medicine*, March 2001, Vol. 161, pp. 749-59.

_____; Lind, April; Margolis, Karen L.; Murdoch, Maureen; McFadden, Rodney; Hauge, Meri; Magnan, Sanne and Drake, Mari. "The Effectiveness of Vaccination against Influenza in Healthy, Working Adults." *The New England Journal of Medicine*, October 1995, Vol. 333, No. 14, pp. 889-93.

COST SAVINGS ASSOCIATED WITH FLU VACCINATIONS IN HEALTHY, WORKING ADULTS

Study	Direct Cost Savings Per Person	Indirect Cost Savings Per Person	Net Cost Savings Per Person
Nichol et al. (1995)	\$5.99	\$40.86	\$46.85
Dille (1999)	\$45.72	\$38.12	\$83.84
Nichol (2001)	-\$6.65	\$20.31	\$13.66

Direct costs used in these studies include the cost of vaccination, the cost of medical care for side effects and the cost of flu averted. Indirect costs consist of time taken away from work for vaccination, work loss due to side effects and potential work loss avoided by not being sick. Net cost savings equals direct cost savings plus indirect cost savings.